For example, STM2457, the first bioavailable small-molecule inhibitor of METTL3, has been shown to significantly impede the development and progression of acute myeloid leukemia (AML) by directly binding to the enzymatic activity of METTL3 and inhibiting the catalytic activity of the METTL3/METTL14 MTC (Yankova et al., 2021). This evidence concerns the gene METTL3 and acute myeloid leukemia.